The FDA under President Trump and new FDA head Martin Makary should rapidly reverse the FDA’s powergrab on laboratory developed tests. To recap, laboratory developed tests (LDTs) are the kind your doctor orders, they are a service not a product and are not sold directly to patients. Congress has never given the FDA the authority […]
The New FDA and the Regulation of Laboratory Developed Tests
The New FDA and the Regulation of Laboratory Developed Tests
28 Dec 2024 Leave a comment
in applied price theory, economics of bureaucracy, economics of regulation, health economics, politics - USA, Public Choice Tags: drug lags
Recent Comments